Skip to main content
Top

Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis

Published in:

Abstract

Neurotrophic keratitis is a rare eye condition characterised by reduced or absent corneal sensation. This leads to impaired corneal healing through a loss of protective mechanisms such as blinking. The cornea becomes vulnerable to persistent epithelial defects, ulceration, infection and ultimately, vision loss or loss of the eye. Treatment strategies aim to protect the corneal surface and promote re-epithelialisation. Established treatments include specialised eye drops such as blood serum eye drops and topical nerve growth factor. In some cases, surgical interventions or procedures such as amniotic membrane transplantation or corneal neurotisation may be necessary. Emerging therapeutic drug options include insulin drops, BRM424, CSB-001 and varenicline. The aim of this Current Opinion is to introduce and review this field for the general reader, paying particular attention to emerging drug therapies for neurotrophic keratitis.
Title
Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis
Authors
Javier Lacorzana
Yan Ning Neo
Laura Maubon
Daniel Sibley
Sajjad Ahmad
Publication date
23-01-2025
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2025
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-025-02147-3
This content is only visible if you are logged in and have the appropriate permissions.

Keynote webinar | Spotlight on innovations in retinal disease

Retinal diseases are a significant cause of vision impairment and blindness worldwide, but the diagnostic and treatment landscape is rapidly evolving. Explore groundbreaking advances in retinal imaging and gene therapy, before taking a deep dive into emerging treatments for wet AMD.

Prof. Giuseppe Querques
Prof. Dr.med. Katarina Stingl
Dr. Miklos Schneider
Watch now
Video
Image Credits
Scarred cornea in neurotrophic keratitis/© 2025, Javier Lacorzana et al, under exclusive licence to Springer Nature Switzerland AG, Drugs, Close-up of eye during optical coherence tomography for high-resolution retinal imaging and diagnostics/© Lucija / Generated with AI / Stock.adobe.com (symbolic image with model)